Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours - Global
Back

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

- 26 September 2024 - 1 mins read

The purpose of the protocol is to determine safety, tolerability, recommended dose (RD), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of IPN60090 as a single agent (Part A) and in combination with pembrolizumab (Part B) or paclitaxel (Part C) in patients with advanced solid tumours and to evaluate food effect (Part D).

Related Clinical Trials

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
26 September 2024 1 mins read

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
26 September 2024 1 mins read

Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
Dysport® Adult Upper Limb Spasticity Extension Study
26 September 2024 1 mins read

Dysport® Adult Upper Limb Spasticity Extension Study
Safety and Efficacy Study of Dysport RU and Glabellar Lines
26 September 2024 1 mins read

Safety and Efficacy Study of Dysport RU and Glabellar Lines
Dysport® Adult Upper Limb Spasticity
26 September 2024 1 mins read

Dysport® Adult Upper Limb Spasticity
Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia
26 September 2024 1 mins read

Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical...
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
26 September 2024 1 mins read

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
26 September 2024 1 mins read

Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome
26 September 2024 1 mins read

Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
26 September 2024 1 mins read

Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia